产品
编 号：F741943
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1006877-41-3
产品详情
生物活性：
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.
体内研究：
Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration.Animal Model:Wild-type male BALB/c mice
Dosage:30 mg/kg and 3 μg/g
Administration:Subcutaneous injection; 30 mg/kg and 3 μg/g
Result:Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05).Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration.Attenuated the CD45 increase (P<0.05).
体外研究：
Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG.
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.
体内研究：
Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration.Animal Model:Wild-type male BALB/c mice
Dosage:30 mg/kg and 3 μg/g
Administration:Subcutaneous injection; 30 mg/kg and 3 μg/g
Result:Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05).Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration.Attenuated the CD45 increase (P<0.05).
体外研究：
Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备